Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries

EuroIntervention

Volumn 6, Issue 1, 2010, Pages 126-133

  Pendyala, Lakshmana K ^a   Yin, Xinhua ^b   Li, Jinsheng ^a   Shinke, Toshiro ^a   Xu, Yawei ^a   Chen, Jack P ^a   King III, Spencer B ^a   Colley, Kenneth ^c   Goodchild, Traci ^a   Chronos, Nicolas ^a   Hou, Dongming ^a  

^a Saint Joseph's Hospital of Atlanta   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c diaDexus Inc   (United States)

Author keywords

Cerivastatin; Drug eluting stents; Endothelial function

Indexed keywords

ACETYLCHOLINE; CERIVASTATIN; EXPRESS; PACLITAXEL; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT; POLYMER; PYRIDINE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BIODEGRADABLE IMPLANT; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY; CYTOTOXICITY; DRUG ELUTING STENT; ENDOTHELIUM CELL; EXPERIMENTAL RABBIT; FIBRIN DEPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; ILIAC ARTERY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MICROSCOPY; MORPHOMETRICS; NEOINTIMA; NONHUMAN; QUANTITATIVE STUDY; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOMOTOR REFLEX; ANIMAL; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; INSTRUMENTATION; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RABBIT; TIME; VASODILATATION;

ANGIOPLASTY, BALLOON; ANIMALS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; HUMANS; ILIAC ARTERY; INHIBITORY CONCENTRATION 50; MYOCYTES, SMOOTH MUSCLE; PACLITAXEL; POLYMERS; PYRIDINES; RABBITS; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 77957276105     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I1A19     Document Type: Article

References (24)

1. Axel DI, Kunert W, Göggelmann C. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645. (Pubitemid 27329445)
2. Chen JP, Hou D, Pendyala L, Goudevenos J A, Kounis NG. Drug-eluting stent thrombosis: the Kounis syndrome revisited. J Am Coll Cardiol Intv 2009;2:583-593.
3. Nebeker JR, Virmani R, Bennett CL. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-181. (Pubitemid 43005183)
4. Kounis NG, Kounis GN, Kouni SN, Soufras GD, Niarchos C, Mazarakis A. Allergic reactions following implantation of drug-eluting stents: A manifestation of Kounis syndrome? J Am Coll Cardiol 2006;48: 592-593.
5. Joner M, Finn AV, Farb A, Mont EK. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006:48:193-202. (Pubitemid 43929240)
6. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-1510. (Pubitemid 46986103)
7. Fukumoto Y, Libby P, Rabkin E. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999. (Pubitemid 32183806)
8. Coradin T, Boissiere M, Livage J. Sol-gel chemistry in medicinal science. Curr Med Chem 2006;13:99-108.
9. Schwartz RS, Edelman ER, Carter A. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-1873.
10. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP, Yeung AC. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 1997;95:1863-1869. (Pubitemid 27164404)
11. Shinke T, Geva S, Pendyala L. Low-Dose Paclitaxel Elution by Novel Bioerodible Sol-gel Coating on Stents Inhibits Neointima with Low Toxicity in Porcine Coronary Arteries. Int J Cardiol 2009;135:93-101.
12. Jaschke B, Michaelis C, Milz S. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005;68:483-489.
13. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005;149:473-481.
14. Sakai M, Kobori S, Matsumura T. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997;133:51-59. (Pubitemid 27322117)
15. Scalia R, Gooszen ME, Jones SP. Simvastatin exerts both antiinflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001;103:598-603.
16. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999;95:229-234. (Pubitemid 29428154)
17. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137:S101-109.
18. Miyauchi K, Kasai T, Yokayama T. Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J 72:832-8, 2008. (Pubitemid 351716691)
19. Shin DI, Kim PJ, Seung KB. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007;48:553-67.
20. Gössl M, Rosol M, Malyar NM. Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. Anat Rec A Discov Mol Cell Evol Biol 2003;272:526-37. (Pubitemid 37238328)
21. Pendyala LK, Li J, Shinke T. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. J Am Coll Cardiol Intv 2009;2:253-62.
22. Pendyala LK, Yin X, Li J, Geva S, et al. The First-generation Drugeluting Stents and Coronary Endothelial Dysfunction. J Am Coll Cardiol Intv 2009;2:1169-1177.
23. Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 2007;93:922-7. (Pubitemid 47122040)
24. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISARSTEREO-2) trial. J Am Coll Cardiol 41:1283-88, 2003. (Pubitemid 36438988)